Concentrations of prostaglandins E, F, and 6-ketoprostaglandin F1rx were estimated in central venous blood and amniotic fluid in 21 women with eclampsia and 16 healthy pregnant controls. Central venous blood concentrations of 6-keto-prostaglandin F1r and prostaglandin E were significantly lower in patients than controls before delivery and remained reduced for at least 48 hours after delivery.
Introduction
Recent evidence of a deficiency of prostacyclin, a vasodilatory prostaglandin, in umbilical arteries,' uterine tissue,2 and amniotic fluid3 in patients with pre-eclampsia has renewed interest in the aetiology of this condition. Despite these reports there has not been unanimity about decreased concentrations of 6-keto-prostaglandin F1r, a metabolite of prostacyclin, in maternal peripheral venous blood. Indeed, Koullapis et al found higher concentrations of 6-keto-prostaglandin F1r and thromboxane B2 in women who developed pre-eclampsia than normotensive pregnant women.4 Data from studies on intrauterine tissues have also not been conclusive.5 6 Such inconsistent results may be due to prostaglandins being labile substances that are rapidly metabolised by the lungs and Medical School, University of Natal, Durban, South Africa J MOODLEY, MB, MRCOG, consultant These significant differences in concentrations of prostaglandin E and 6-keto-prostaglandin Fl, were also found at the time of operation (p < 0 001) and at 24 and 48 hours after delivery (p < 0 0005). Analysis of the variance within the groups of women with and without eclampsia by the Friedman procedure indicated that there was no significant change within the two groups in any of the prostaglandins during the time of the study. Prostaglandin concentrations in amniotic fluid-Median concentrations (and ranges) of prostaglandins E, F, and 6-keto-prostaglandin F,, in amniotic fluid were 1-64 (1-12-3 07) nmol/l (57 9 (39-5-108 4 ng/ 100 ml), 0 55 (0 44-0-75) nmol/l (26 5 (21 2-36-1) ng/100 ml), and 0 51 (0 25-1-25) nmol/l (18 9 (9 3-46-4) ng/100 ml) respectively in patients and 2 90 (1 41-4 33) nmol/l (102 4 (49 8-152-8) ng/100 ml), 0 81 (0-38-1 81) nmol/l (40 8 (18-3-87-1) ng/100 ml, and 0-41 (0-12-0 92) nmol/l (15 5 (4 5-34 5) ng/100 ml) in controls. Thus there were no significant differences in amniotic fluid concentrations between patients and controls.
Discussion
Controversy about the definition of pre-eclampsia and its severity has complicated previous studies on the role of prostaglandins in the pathophysiology of this condition. We sought to obviate these problems by investigating patients who had developed eclampsia as evidenced by severe proteinuric hypertension with convulsions. They were therefore relatively homogeneous in respect of the severity of the condition.
Other studies have, of necessity, measured peripheral venous concentrations of prostaglandins with the inherent problems of metabolism of some primary prostaglandins after circulation through the lungs. In the present investigation these compounds were measured in central venous blood before passage through the lungs. Although the concentrations were considerably higher than those measured by mass spectrometry, 9 those in the controls were within limits normally obtained by radioimmunoassay in pregnancy. The significantly decreased plasma concentrations of prostaglandins E and 6-keto-prostaglandin F1, are therefore of great importance (table) . Although an effect of the drug treatment cannot be excluded, we are not aware of any effect of magnesium sulphate on production of prostaglandins; the low concentrations seen before treatment was started and the unchanged concentrations 24 hours after magnesium was stopped militate against a drug induced effect. Thus the low concentrations of vasodilatory prostaglandins were probably directly related to the pathogenesis of eclampsia. By contrast, the concentrations of all prostaglandins in amniotic fluid were not significantly different between the patients and controls. This accords with our previous observations that concentrations of 6-keto-prostaglandin F1, and thromboxane B2 are not altered in amniotic fluid obtained from pregnant women before the onset of eclampsia and supports the contention that abnormalities in production of prostanoids in pre-eclampsia are reflected in vascular tissue rather than in the membranes and deciduums. 10 Gant et al proposed that the relative vascular refractoriness to angiotensin II that characterises normal pregnancy results from the action of a prostaglandin or prostaglandin related substance on vascular smooth muscle.11 In pre-eclampsia a deficiency of the prostaglandin may increase sensitivity and play a part in enhanced vascular sensitivity to circulating vasoconstrictor substances. Prostaglandin E and prostacyclin could theoretically satisfy the criteria for this vasodepressor prostanoid, although Barrow et al suggested that the concentrations of prostaglandin I2 in maternal plasma are too low for it to act as a circulating hormone in normal pregnancy.9 This does not exclude a local effect in the uterine and placental vessels, however, and several studies have shown that maternal and fetal vessels produce less prostaglandin 12 in pre-eclampsia.1' The present study showed an appreciable reduction in concentrations of prostaglandins and keto-prostaglandin Fl. in patients with eclampsia, which persisted for at least 48 hours after delivery. This suggests that, although the uteroplacental vessels may be the major source of increased production of prostacyclin in pregnancy, a more generalised deficiency of vasodilatory prostaglandins may be present in severe pre-eclampsia and eclampsia. It also raises the possibility that infusion of prostacyclin may be important in treating the life threatening condition eclampsia. 
